Hochschulschrift
Effektivität und Sicherheit des 3.-Generations-EGFR-Tyrosinkinaseinhibitors Osimertinib im unselektierten Patientenkollektiv
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Dimensions
-
21 cm
- Extent
-
112 Seiten
- Language
-
Deutsch
- Notes
-
Diagramme
Literaturverzeichnis: Seite 88-103
Johann Wolfgang Goethe-Universität Frankfurt am Main, Dissertation, 2019
- Keyword
-
Epidermaler Wachstumsfaktor-Rezeptor
Patient
Nicht-kleinzelliges Bronchialkarzinom
Therapie
- Event
-
Veröffentlichung
- (where)
-
Frankfurt am Main
- (when)
-
2018
- Creator
- Contributor
- Table of contents
- Rights
-
Bei diesem Objekt liegt nur das Inhaltsverzeichnis digital vor. Der Zugriff darauf ist unbeschränkt möglich.
- Last update
-
11.06.2025, 1:44 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Object type
- Hochschulschrift
Time of origin
- 2018
Other Objects (12)
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases
Correction to: Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Osimertinib : Therapieplanung und Therapiesequenzen beim fortgeschrittenen EGFR-mutierten NSCLC
Osimertinib : Resistenz bei EGFR-mutiertem NSCL unter TKI-Behandlung
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Overcoming EGFR G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors
Osimertinib as treatment for EGFR exon 20 insertion-positive lung adenocarcinoma
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC
Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs
Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M
The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells
Subsequent treatments beyond progression on osimertinib in EGFR-mutated NSCLC and leptomeningeal metastases